Oruka Therapeutics (NASDAQ:ORKA) Shares Up 9.5% – Here’s Why

Oruka Therapeutics, Inc. (NASDAQ:ORKA)’s share price shot up 9.5% on Thursday . The company traded as high as $61.88 and last traded at $62.6320. 376,265 shares changed hands during trading, a decline of 64% from the average session volume of 1,055,575 shares. The stock had previously closed at $57.20.

Analyst Upgrades and Downgrades

ORKA has been the subject of a number of research reports. Stifel Nicolaus increased their price target on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Leerink Partners set a $120.00 price target on shares of Oruka Therapeutics in a research note on Thursday, April 30th. Wedbush set a $165.00 price objective on Oruka Therapeutics in a research report on Monday, April 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, April 21st. Finally, HC Wainwright reissued a “buy” rating on shares of Oruka Therapeutics in a research report on Wednesday. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $131.30.

Oruka Therapeutics Price Performance

The stock’s 50 day simple moving average is $60.66 and its two-hundred day simple moving average is $42.22. The firm has a market cap of $3.83 billion, a P/E ratio of -32.58 and a beta of -0.26.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.04. Equities research analysts anticipate that Oruka Therapeutics, Inc. will post -2.05 earnings per share for the current year.

Insider Activity

In related news, Director Carl Dambkowski sold 105,000 shares of the stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $58.97, for a total transaction of $6,191,850.00. Following the sale, the director directly owned 73,743 shares of the company’s stock, valued at approximately $4,348,624.71. This represents a 58.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $61.85, for a total value of $432,950.00. Following the transaction, the insider directly owned 33,377 shares in the company, valued at approximately $2,064,367.45. The trade was a 17.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 139,055 shares of company stock valued at $8,095,785. Company insiders own 23.49% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Fairmount Funds Management LLC raised its holdings in Oruka Therapeutics by 9.9% during the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock valued at $71,252,000 after acquiring an additional 333,340 shares during the period. Secure Asset Management LLC bought a new position in Oruka Therapeutics during the 4th quarter valued at about $2,475,000. Avoro Capital Advisors LLC purchased a new stake in shares of Oruka Therapeutics during the third quarter valued at $25,640,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new stake in shares of Oruka Therapeutics during the third quarter valued at $296,000. Finally, Commodore Capital LP raised its position in Oruka Therapeutics by 23.5% during the 3rd quarter. Commodore Capital LP now owns 1,753,054 shares of the company’s stock valued at $33,711,000 after purchasing an additional 333,340 shares in the last quarter. 56.44% of the stock is owned by hedge funds and other institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.